Genome‑repair startups vs regulation

Startups focused on repairing accumulated structural DNA damage are moving from lab concepts to first human trials, aiming to treat aging's root causes rather than downstream symptoms. That transition exposes a near-term bottleneck where regulatory frameworks, not scientific feasibility, may determine deployment speed and who benefits. — If companies like Matter Bio succeed, the debate will shift from 'can we?' to 'who gets access, under what oversight, and what risks do we accept?', affecting health policy, equity, and biotech governance.